Request Demo
Last update 31 Jan 2026
PF-07261271
Last update 31 Jan 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms PF-07261271, RG6730, RO7837195 |
Target |
Action inhibitors |
Mechanism IL-12p40 inhibitors(Interleukin-12 subunit beta inhibitors), TL1A inhibitors(Tumor necrosis factor superfamily member 15 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with PF-07261271NCT06979336
A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT05536440
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS
100 Clinical Results associated with PF-07261271
Login to view more data
100 Translational Medicine associated with PF-07261271
Login to view more data
100 Patents (Medical) associated with PF-07261271
Login to view more data
100 Deals associated with PF-07261271
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Phase 2 | United States | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | China | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Japan | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Australia | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Brazil | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Canada | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Czechia | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | France | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | Germany | 26 Aug 2025 | |
| Colitis, Ulcerative | Phase 2 | India | 26 Aug 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 35 | placebo+PF-07261271 (SAD: Placebo) | whoztjgweo = hfdvohkwyd befonblnrv (eiysbqrzbr, agmtpvcqrp - motkbzklhr) View more | - | 24 Mar 2025 | ||
(SAD: PF-07261271 Dose Level 1) | whoztjgweo = dlhmdivfhc befonblnrv (eiysbqrzbr, osepfycgwe - rfikblcmhu) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free